KYMRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Kymera Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$108.07+3.29 (+3.14%)
Close on Oct 19, 2026
- Market cap
- $10.61B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2018 to 2025
Gross margin
0.0%
Operating margin
-891.1%−755.0 pts over 5 years
Net margin
-794.0%−660.1 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -16.7% | -5.7% | +2.9% | – |
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -43.5% | -25.8% | |
| Return on assets | – | -15.1% | -22.9% | |
| Current ratio | – | 2.73 | 10.47 | |
| Capex to revenue | – | 26.7% | 3.7% | |
| Diluted shares | – | 17M | 84M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Kymera Therapeutics generated $812.25M from operations and spent $53.20M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$812.25M
Used
$53.20M
Capital expenditure$53.20M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-794.0%
×Asset turnover0.03×
×Equity multiplier1.13×
=Return on equity, FY2025-25.8%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -794.0% | 0.03× | 1.13× | -25.8% |
| FY2024 | -475.6% | 0.06× | 1.26× | -36.4% |
| FY2023 | -187.0% | 0.13× | 1.33× | -33.2% |
| FY2022 | -330.6% | 0.08× | 1.27× | -32.6% |
| FY2021 | -137.6% | 0.13× | 1.47× | -27.0% |
| FY2020 | -134.0% | 0.11× | 2.88× | -43.5% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$311.35M
- Cash generatingOperating cash flow above zero-$232.89M
- Return on assets improvedROA up on the prior year-38.9% → -31.8%
- Earnings backed by cashOperating cash flow above net income-$232.89M vs -$311.35M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose7.53 → 10.47
- No dilutionShare count did not rise75M → 84M
- Gross margin improvedGross margin up on the prior year0.00% → 0.00%
- More efficientAsset turnover rose0.08 → 0.04